Eventide Gilead Fund Announces<br /> 2012 Results
BOSTON, MA–(Marketwire – Jan 22, 2013) – The Eventide Gilead Fund ( NASDAQ : ETGLX ), a mutual fund practicing biblically responsible investing, achieved a one-year total return of 18.15%, compared with the Russell Mid-Cap Growth Index return of 15.81% and S&P 500 Index return of 16.00%, outperforming each by 2.34% and 2.15% (respectively). The Fund finished the year ranking in the top 8% of its peer group (Mid-Cap Growth) for total performance according to Morningstar, out of 400 funds.
The following table shows the Gilead Fund’s performance since inception:
|As of 12/31/2012||YTD return||1 year return||3 year annualized return||Since inception (7/08/2008) annualized return|
|Eventide Gilead Fund*||18.15%||18.15%||11.95%||11.08%|
|S&P 500 Total Return Index||16.00%||16.00%||10.87%||4.88%|
|Russell Mid-Cap Growth Total Return Index||15.81%||15.81%||12.91%||6.00%|
The Eventide Gilead Fund maintains its distinctive investment strategy of finding and investing in companies that “serve — or ‘create value,'” said Eventide lead portfolio manager Finny Kuruvilla, MD PhD. “Value creation is the business application of ‘the golden rule,’ the hallmark of the Christian ethic, but also, we believe, the key indicator of business vitality and the most reliable leading indicator of financial performance.”
“Businesses that prosper best over the long-term are those that serve important needs especially well; those that lose sight of this purpose invariably shift focus inwardly to shareholders, where brand posturing and ‘next quarter’-thinking cost meaningful innovation — and eventually profits,” continued Kuruvilla. “Our commitment to looking for companies that serve, however, we believe has been precisely the reason Gilead Fund investors have benefited over the past four and half years, including in 2012.”
The Eventide Gilead Fund is managed by Eventide Asset Management, LLC, a Boston-based investment advisor.
Expenses ratios: Gross Expenses 2.05%; Net Expenses 1.64%. The advisor has agreed to maintain the Fund’s total annual operating expenses at 1.64% until at least October 31, 2013. Three-year and inception returns are annualized. The performance data quoted here represents past performance. Current performance may be lower or higher than the performance data quoted above. Past performance is no guarantee of future results. The investment return and principal value of an investment will fluctuate so that investor’s shares, when redeemed, may be worth more or less than their original cost. Please review the fund’s prospectus for more information regarding the fund’s fees and expenses. Performance shown is for No-load Class shares (please see a prospectus for information about other share classes). For performance information current to the most recent month-end, please call toll-free 877-771-EVEN (3836).
Morningstar ratings and classifications do not constitute and are not intended to constitute investment advice. As a result, you should not make an investment decision on the basis of this information. Rather, you should use Morningstar ratings and classifications for informational purposes only.
The S&P 500 is an index created by Standard & Poor’s Corp considered to represent the performance of the stock market generally. The Russell Midcap Growth Index measures the performance of the U.S. equity mid-cap growth segment. It includes mid-cap companies with higher price-to-book ratios and forecasted growth. Neither index is an investment product available for purchase.
Mutual Funds involve risk including the possible loss of principal. The fund can invest in smaller-sized companies which may experience higher failure rates than larger companies and they normally have a lower trading volume than larger companies. The Fund’s ethical values screening criteria could cause it to underperform similar funds that do not have such screening criteria. The fund can have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. The fund can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. The fund can have risk associated with a higher portfolio turnover which could result in higher transactional costs.
An investor should consider the Fund’s investment objectives, risks, charges and expenses carefully before investing or sending money. This and other important information about the Eventide Gilead Fund can be found in the Fund’s prospectus. Please read the prospectus carefully before investing.
To obtain a current prospectus please call the fund, toll free at 877-771- EVEN (3836).
The Eventide Gilead Fund is distributed by Northern Lights Distributors, LLC, which is not affiliated with Eventide
Asset Management, LLC.
877-771-EVEN (3836), x55